Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.
Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the treatment of pneumonia and empyema caused by susceptible staphylococci in some parts of the world (e.g. Canada).
Application: Administered typically as a combination drug product used in topical creams, powders, ointments and solutions. Bacitracin is also administered systemically as intramuscular injections in some parts of the world (e.g. Canada).
Product grades |
Sterile, non-micronized Non-sterile, micronized Non-sterile, non-micronized | |||||
Compliance |
Ph. Eur. USP |
|||||
Manufacturing site |
Xellia (Taizhou) Pharmaceuticals Co., Ltd., China (non-sterile) Xellia Pharmaceuticals ApS, Copenhagen, Denmark (sterilisation only) |
|||||
Release site |
Xellia (Taizhou) Pharmaceuticals Co., Ltd., China (non-sterile) Xellia Pharmaceuticals ApS, Copenhagen, Denmark (sterile) |
|||||
Site registered |
EU GMP issued by Danish Medicines Agency US FDA |
|||||
Regulatory documentation |
EU Drug Master File (DMF)/Certificate of Suitability (CEP) US Drug Master File (DMF) Letter of Access (LoA) |
|||||
Packaging sizes |
|
|||||
Packaging material |
|
|||||
Shelf life |
| |||||
Storage conditions |
| |||||
Other documentations |
| |||||
